Alcoholic liver disease. Clinical example

Alcoholic liver disease (ALD) is one of the major liver diseases associated with high mortality rates. There are about 3 million alcohol-related deaths worldwide every year. ALD covers the spectrum of liver damage ranging from asymptomatic steatosis, alcoholic steatohepatitis and fibrosis to cirrhosis. In addition, patients may suffer from acute and chronic liver failure, alcoholic hepatitis (AH), bleeding from esophageal or gastric varices, ascites, coagulopathy, hepatic encephalopathy and liver cancer. In most patients, AH is diagnosed at advanced stages of the disease with higher complication and mortality rates. Patients abusing alcohol may simultaneously have viral hepatitis B or C, genetic diseases such as alpha-1 antitrypsin deficiency or hemochromatosis. The clinical manifestations of the disease are very diverse. There is no special laboratory test to detect the alcoholic cause of liver damage. A liver biopsy in the context of alcohol abuse in the history is a diagnostic test, but is not indicated for all patients. The main focus of therapy for ALD patients regardless of the stage of the disease is prolonged alcoholic abstinence. Abstinence is also the main key to preventing alcoholic liver diseases. Corticosteroids provide short-term survival improvement in about half of the patients with severe AH, and long-term survival is related to the severity of the underlying liver disease and depends on alcohol abstinence. General therapeutic measures in patients hospitalized with ALD include inpatient treatment of complications, treatment of alcohol withdrawal syndrome, monitoring of concomitant infectious diseases and their early effective antibiotic therapy, addition of hepatoprotectors to therapy regimens, and treatment of the underlying alcohol-related disorder. Liver transplantation (LT) is the final treatment option in patients with decompensated alcoholic liver cirrhosis. LT may also be considered in individual patients with AH who do not respond to drug therapy. Existing AH treatment regimens have insufficient efficacy, therefore, development of new methods and regimens of ALD targeted therapy is required. In this article we will consider the pathogenesis and treatment of ALD, paying more attention to AH, its topical and promising methods of treatment.

1. Yoon Y-H., Chen C.M. Surveillance Report #105. Liver cirrhosis mortality in the United States: national, state, and regional trends, 2000-2013. 2016. Available at: https://pubs.niaaa.nih.gov/publications/surveillance105/Cirr13.pdf.

2. Stein E., Cruz-Lemini M., Altamirano J., Ndugga N., Couper D., Abraldes J.G., Bataller R. Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. J Hepatol. 2016;65(5):998-1005. doi: 10.1016/j.jhep.2016.06.018.

3. Sheron N. Alcohol and liver disease in Europe - simple measures have the potential to prevent tens of thousands of premature deaths. J Hepatol. 2016;64(4):957-967. doi: 10.1016/j.jhep.2015.11.006.

4. Ivashkin V.T., Mayevskaya M.V., Pavlov C.S., Sivolap Y.P., Lunkov V.D., Zharkova M.S., Maslennikov R.V. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(6):20-40. (In Russ.) doi: 10.22416/1382-4376-2017-27-6-20-40.

5. Mayevskaya M.V., Bakulin I.G., Chirkov A.A., Lyusina Y.O., Lun'kov V.D. Alcohol abuse in gastroenterological patients. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(4):24-35. (In Russ.) doi: 10.22416/1382-4376-2016-26-4-24-35.

6. Chacko K.R., Reinus J. Spectrum of Alcoholic Liver Disease. Clin Liver Dis. 2016;20(3):419-427. doi: 10.1016/j.cld.2016.02.002.

7. Torruellas C., French S.W., Medici V. Diagnosis of alcoholic liver disease. World J Gastroenterol. 2014;20(33):11684-11699. doi: 10.3748/wjg.v20.i33.11684.

8. Farooq M.O., Bataller R. Pathogenesis and Management of Alcoholic Liver Disease. Dig Dis. 2016;34(4):347-355. doi: 10.1159/000444545.

9. Flegel K., MacDonald N., Hebert PC. Binge drinking: all too prevalent and hazardous. Can Med Assoc J. 2011;183(4):411. doi: 10.1503/cmaj.110029.

10. Shipman K.E. Clinical biochemistry: Metabolic and clinical aspects (3rd edg.) Ann Clin Biochem. 2015;52(2). doi: 10.1177/0004563214545705.

11. Kong L.Z., Chandimali N., Han Y.H., Lee D.H., Kim J.S., Kim S.U. et al. Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver Disease. Int J Mol Sci. 2019;20(11):2712. doi: 10.3390/ijms20112712.

12. Ceni E., Mello T., Galli A. Pathogenesis of alcoholic liver disease: Role of oxidative metabolism. World J Gastroenterol. 2014;20(47):17756-17772. doi: 10.3748/wjg.v20.i47.17756.

13. Keshavarzian A., Farhadi A., Forsyth C.B., Rangan J.,Jakate S., Shaikh M. et aL. Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol. 2009;50(3):538 — 547. doi: 10.1016/j.jhep.2008.10.028.

14. Keshavarzian A., Farhadi A., Forsyth C.B., Rangan J., Jakate S., Shaikh M. et al. Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol. 2009;50(3):538-547. doi: 10.1016/j.jhep.2008.10.028.

15. Polunina T.E. Alcoholic liver disease. Farmateka = Pharmateka. 2019;26(2):106-114. (In Russ.) doi: 10.18565/pharmateca.2019.2.106-114.

16. Maev I.V., Abdurakhmanov D.T., Andreev D.N., Dicheva D.T. Alcoholic liver disease: State-of-the-art. Terapevticheskiy arkhiv = Therapeutic Archive.2014;86(4):108-111. (In Russ.) Available at: https://www.medias-phera.ru/issues/terapevticheskij-arkhiv/2014/4/030040-36602014419.

17. Singal A.K., Bataller R., Ahn J., Kamath P.S., Shah V.H. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-194. doi: 10.1038/ajg.2017.469.

18. Thursz M., Gual A., Lackner C., Mathurin P., Moreno C., Sahr L. et al. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. Journal of Hepatology. 2018;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018.

19. Jonas D.E., Amick H.R., Feltner C., Bobashev G., Thomas K., Wines R. et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and metaanalysis. JAMA. 2014;311(18):1889-900. doi: 10.1001/jama.2014.3628.

20. Addolorato G., Leggio L., Ferrulli A., Cardone S., Vonghia L., Mirijello A. et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind con-trolled study. Lancet. 2007;370(9603):1915-1922. doi: 10.1016/S0140-6736(07)61814-5.

21. Leggio L., Lee M.R. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med. 2017;130(2):124-134. doi: 10.1016/j.amjmed.2016.10.004.

22. Ilchenko L.Yu. Russian Ademetionine Preparation: Ten-Year Experience of Using It in Alcoholic Liver Disease. Doktor.Ru = Doctor.Ru. 2015;12(113):14-18. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=24373834.

23. Guo T., Chang L., Xiao Y., Liu Q. S-Adenosyl-L-Methionine for the Treatment of Chronic Liver Disease: A Systematic Review and Meta-Analysis. PLoS ONE. 2015;10(3):e0122124. doi: 10.1371/journal.pone.0122124.

24. Guo T., Chang L., Xiao Y., Liu Q. S-Adenosyl-L-Methionine for the Treatment of Chronic Liver Disease: A Systematic Review and Meta-Analysis. PLoS ONE. 2015;10(3):e0122124. doi: 10.1371/journal.pone.0122124.

25. Mato J.M., Camara J., Fernandez de Paz J., Caballeria L., Coll S., Caballero A. et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30(6):1081-1089. doi: 10.1016/s0168-8278(99)80263-3.

26. Gundermann K., Gundermann S., Drozdzik M., Prasad M.V. Essential phospholipids in fatty liver: a scientific update. Clin Exp Gastroenterol. 2016. 2016(9):105-117. doi: 10.2147/CEG.S96362.

27. Mordasova V.I. Heptor in the treatment of alcoholic liver disease. RMZH = RMJ. 2010;(13):824-830. (In Russ.) Available at: https://www.rmj.ru/arti-cles/bolezni_organov_pishchevareniya/Geptor_v_lechenii_alkogolynoy_bolezni_pecheni/.

28. Collell A., Garcia-Ruiz C., Miranda M., Ardite E., Mari M., Morales A. et al. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology. 1998;115(6):1541-1551. doi: 10.1016/s0016-5085(98)70034-4.

29. Garica-Ruiz C., Morales A., Colell A., Ballesta A., Rodes J., Kaplowitz N. et al. Feeding S-adenosyl-L-methionine attenuates both ethanol-induced depletion of mitochondrial glutathione and mitochondrial dysfunction in periportal and perivenous rat hepatocytes. Hepatology. 1995;21(2):207-214. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7806156.10.1002/hep.1840210133.

30. Podymova S.D. Ademetionine: pharmacological effects and clinical application of the drug. RMZH = RMJ. 2010;(13):800-806. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_organov_pishchevareniya/Ademetionin_farmakologicheskie_effekty_i_klinicheskoe_primenenie_pre-parata/